8.2.3 Antimuscarinics & others Summary

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/37

encourage image

There's no tags or description

Looks like no tags are added yet.

38 Terms

1
New cards

Primary therapeutic purpose of muscarinic cholinergic antagonists in airway disease

Prevent bronchoconstriction and mucus production by blocking acetylcholine on airway muscarinic receptors

2
New cards

Diseases treated with antimuscarinics

Asthma and COPD, more commonly COPD

3
New cards

Mechanism by which antimuscarinic drugs improve airflow

Compete with acetylcholine at muscarinic receptors, reducing parasympathetic-mediated airway narrowing

4
New cards

Examples of antimuscarinic agents used in airway disease

Ipratropium, tiotropium, umeclidinium

5
New cards

Role of LAMAs in asthma therapy

Used in combination with inhaled corticosteroids for chronic control

6
New cards

Common systemic adverse effects of antimuscarinic therapy

Dry mouth, blurred vision, constipation, urinary retention, confusion

7
New cards

Cause of bad taste particularly with ipratropium

Local effect in oropharynx

8
New cards

Reason nebulized antimuscarinics may worsen glaucoma

Drug can reach ocular tissue during nebulization

9
New cards

Primary PDE4 inhibitor used for COPD

Roflumilast

10
New cards

Indication of PDE4 inhibitors

Severe COPD with history of exacerbations (not for acute bronchospasm)

11
New cards

Clinical benefit of dual PDE3/4 inhibition

Additive anti‑inflammatory and bronchodilatory effects

12
New cards

Mechanistic result of PDE4 inhibition in airways

Increased cAMP, reduced inflammatory cells and cytokines, decreased bronchoconstriction

13
New cards

Common side effects of PDE4 inhibitors

Diarrhea, weight loss, nausea, headache in 5‑10% of patients

14
New cards

Pharmacokinetic features of PDE4 inhibitor

Oral bioavailability ~80%; active metabolite; metabolized by CYP1A2 and CYP3A4

15
New cards

Important drug interactions with PDE4 inhibitors

Rifampin induces metabolism; ketoconazole and erythromycin inhibit metabolism

16
New cards

PDE4 inhibitor contraindication

Moderate or severe hepatic impairment (Child‑Pugh B or C)

17
New cards

Therapeutic purpose of leukotriene modifiers

Manage chronic asthma by targeting leukotriene‑mediated inflammation and bronchoconstriction

18
New cards

Administration route of leukotriene modifiers

Oral

19
New cards

Drug that inhibits 5‑lipoxygenase

Zileuton

20
New cards

Drugs that block leukotriene receptors

Montelukast, pranlukast, zafirlukast

21
New cards

Physiologic result of leukotriene receptor antagonism

Reduced bronchoconstriction, fewer eosinophils recruited, decreased mucus secretion

22
New cards

Metabolic pathways relevant to montelukast

Substrate of CYP3A4 and CYP2C9

23
New cards

Reported side effects of leukotriene modifiers

Headache, nausea, abdominal pain, cough; possible liver enzyme elevation

24
New cards

Black box warning associated with leukotriene modifiers

Neuropsychiatric reactions reported in 2020, not for zafirlukast

25
New cards

Mechanism of omalizumab

Binds IgE, prevents mast cell activation and allergic inflammatory cascade

26
New cards

Clinical use of omalizumab

Severe allergic asthma

27
New cards

Administration of omalizumab

Subcutaneous every 2-4 weeks

28
New cards

Dependence of omalizumab dosing

Body weight and IgE level

29
New cards

Examples of anti‑IL‑5 monoclonal antibodies

Mepolizumab and reslizumab

30
New cards

Benralizumab mechanism

Binds IL‑5 receptor

31
New cards

Dupilumab mechanism

Binds IL‑4 receptor

32
New cards

Common requirement for monoclonal antibody administration

Must be given in a setting equipped to manage anaphylaxis

33
New cards

Important precaution when starting monoclonal antibody therapy

Do not abruptly discontinue inhaled corticosteroids

34
New cards

Reported side effects of monoclonal antibodies

Arthralgia, fatigue, dizziness, pruritus, dermatitis, injection‑site reactions, rare anaphylaxis

35
New cards

Purpose of ICS + LABA combinations

Complementary short‑term and long‑term control of airway inflammation and bronchoconstriction

36
New cards

Examples of ICS + LABA combinations

Budesonide + formoterol, fluticasone propionate + salmeterol, fluticasone furoate + vilanterol

37
New cards

Purpose of LAMA + LABA combinations in COPD

Dual bronchodilation by muscarinic blockade and β2 stimulation

38
New cards

Examples of triple therapy components

Corticosteroid, long‑acting muscarinic antagonist, and long‑acting β2‑agonist